Dichinalex
Categoria
Dichinalex Marchi, Dichinalex Analoghi
- 3377 RP opalate
- Amokin
- Aralen
- Aralen HCl
- Arechin
- Arthrochin
- Artrichin
- Avlochlor
- Avloclor
- Bemaco
- Bemaphate
- Bemasulph
- Benaquin
- Bipiquin
- Capquin
- Chemochin
- Chingamin
- Chloraquine
- Chlorochin
- Chlorochine
- Chloroquina
- Chloroquine (VAN)
- Chloroquine Phosphate
- Chloroquinium
- Chlorquin
- Cidanchin
- Clorochina
- Cocartrit
- Delagil
- Dichinalex
- Elestol
- Gontochin
- Heliopar
- Hydroxychloroquine Sulfate
- Imagon
- Iroquine
- Klorokin
- Lapaquin
- Malaquin
- Malaren
- Malarex
- Mesylith
- Neochin
- Nivachine
- Nivaquine
- Nivaquine B
- Nivaquine [as sulfate]
- Pfizerquine
- Plaquenil
- Quinachlor
- Quinagamin
- Quinagamine
- Quinercyl
- Quingamine
- Quinilon
- Quinoscan
- Resochen
- Resochin
- Resoquina
- Resoquine
- Reumachlor
- Reumaquin
- Roquine
- Sanoquin
- Silbesan
- Siragan
- Solprina
- Sopaquin
- Tanakan
- Tresochin
- Trochin
Dichinalex Marchi miscela
Dichinalex Formula chimica
C18H26ClN3
Dichinalex RX link
http://www.rxlist.com/cgi/generic2/hquine2.htm
Dichinalex FDA foglio
Dichinalex DMS (foglio di materiale di sicurezza)
Dichinalex Sintesi di riferimento
Nessuna informazione disponibile
Dichinalex Peso molecolare
319.872 g/mol
Dichinalex Temperatura di fusione
289 oC
Dichinalex H2O Solubilita
10,6 mg / L
Dichinalex Stato
Solid
Dichinalex LogP
4.474
Dichinalex Forme di dosaggio
Compressa
Dichinalex Indicazione
Per il trattamento soppressivo e per attacchi acuti di malaria a causa di P. vivax, P.malariae, P. ovale, e ceppi sensibili di P. falciparum, l'agente di seconda linea nel trattamento dell'artrite reumatoide
Dichinalex Farmacologia
Clorochina è l'anti droga prototipo di malaria, più ampiamente utilizzati per trattare tutti i tipi di malaria, fatta eccezione per la malattia causata da Plasmodium falciparum resistente alla clorochina. È altamente efficace contro eritrocitaria forme di Plasmodium vivax, Plasmodium ovale e Plasmodium malariae, ceppi sensibili di Plasmodium falciparum e gametociti di Plasmodium vivax. Essendo alcalino, il farmaco raggiunge concentrazioni elevate all'interno dei vacuoli alimentari del parassita e aumenta il pH. Si trova a indurre una rapida aggregazione del pigmento. Clorochina inibisce la polimerasi parassita eme enzima che converte l'eme tossici in non tossico hemazoin, provocando l'accumulo di eme tossici all'interno del parassita. Si può anche interferire con la biosintesi degli acidi nucleici.
Dichinalex Assorbimento
Completamente assorbito dal tratto gastrointestinale
Dichinalex Tossicita
Nessuna informazione disponibile
Dichinalex Informazioni paziente
PATIENT INFORMATION
Complete blood cell counts should be made periodically if patients are given prolonged therapy. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered. The drug should be administered with caution to patients having G-6-PD (glucose-6 phosphate dehydrogenase) deficiency.
In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patient closely observed.
Since this drug is known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs.
Patients with history of epilepsy should be advised about the risk of chloroquine provoking seizures.
Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother.
Irreversible retinal damage has been observed in some patients who had received long-term or high-dosage 4-aminoquinoline therapy. Retinopathy has been reported to be dose related.
Follow Rxlist link and drugs.com link for detailed patient information.
Complete blood cell counts should be made periodically if patients are given prolonged therapy. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered. The drug should be administered with caution to patients having G-6-PD (glucose-6 phosphate dehydrogenase) deficiency.
In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patient closely observed.
Since this drug is known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs.
Patients with history of epilepsy should be advised about the risk of chloroquine provoking seizures.
Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother.
Irreversible retinal damage has been observed in some patients who had received long-term or high-dosage 4-aminoquinoline therapy. Retinopathy has been reported to be dose related.
Follow Rxlist link and drugs.com link for detailed patient information.
Dichinalex Atto interessato organismi
Plasmodium
